Elagolix: First global approval

Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700089 · Cited by 511 · see citing works

Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies

Surrey, E., Taylor, H. S., Giudice, L., Lessey, B. A., Abrao, M. S., Archer, D. F., Diamond, M. P., Johnson, N. P., Watts, N. B., Gallagher, J. C., et al. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002675 · Cited by 139 · see citing works

Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix

Struthers, R. S., Nicholls, A. J., Grundy, J. S., Chen, T., Jimenez, R., Yen, S. S. C., & Bozigian, H. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1695 · Cited by 127 · see citing works

Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

Diamond, M. P., Carr, B. R., Dmowski, W. P., Koltun, W. D., O'Brien, C. F., Jiang, P. X., Burke, J., Jimenez, R., Garner, E. I. O., & Chwalisż, K. (2013) · Reproductive Sciences · doi:10.1177/1933719113497292 · Cited by 121 · see citing works

Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: Effects on bone mineral density

Carr, B., Dmowski, W. P., O’Brien, C., Jiang, P., Burke, J., Jimenez, R., Garner, E., & Chwalisz, K. (2014) · Reproductive Sciences · doi:10.1177/1933719114549848 · Cited by 114 · see citing works

Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women

Ng, J., Chwalisz, K., Carter, D. C., & Klein, C. E. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3845 · Cited by 110 · see citing works

Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study

Archer, D. F., Stewart, E. A., Jain, R. I., Feldman, R., Lukes, A. S., North, J., Soliman, A. M., Gao, J., Ng, J., & Chwalisż, K. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.05.006 · Cited by 82 · see citing works

Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study

Carr, B. R., Giudice, L. C., Dmowski, W. P., O’Brien, C., Jiang, P. X., Burke, J., Jimenez, R., Hass, S., Fuldeore, M. J., & Chwalisż, K. (2013) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.5301/je.5000157 · Cited by 64 · see citing works

Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist: Results from a Phase 2, Randomized Controlled Study

Ács, N., O’Brien, C., Jiang, P. X., Burke, J., Jimenez, R., Garner, E. I. O., & Chwalisż, K. (2015) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.5301/je.5000211 · Cited by 31 · see citing works

Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis

Winzenborg, I., Nader, A. M., Polepally, A. R., Liu, M., Degner, J. F., Klein, C. E., Mostafa, N. M., Noertersheuser, P. A., & Ng, J. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0629-6 · Cited by 27 · see citing works

Elagolix Alone and With Add-Back Decreases Heavy Menstrual Bleeding in Women With Uterine Fibroids [21H]

Stewart, E. A., Owens, C. D., Duan, W. R., Gao, J., Chwalisż, K., & Simon, J. A. (2017) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000514923.67415.29 · Cited by 4 · see citing works

Elagolix improves quality of life in women with heavy menstrual bleeding associated with uterine fibroids: evidence from a phase 2B randomized trial

Diamond, M., Soliman, A. M., Gao, J., Owens, C., Chwalisż, K., & Archer, D. F. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.07.095 · Cited by 4 · see citing works

Elagolix treatment in women with heavy menstrual bleeding-associated with uterine fibroids: efficacy and safety results from a phase 2B study

Simon, J. A., Stewart, E. A., Owens, C., Duan, W. R., Gao, J., & Chwalisż, K. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.07.094 · Cited by 3 · see citing works

U.S. FDA Approved Drugs from 2015–June 2020: A Perspective

Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815 · see citing works

G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery

Zhang, M., Chen, T., Lu, X., Lan, X., Chen, K., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 520 · see citing works

Fluorine‐Containing Drugs Approved by the FDA in 2018

Mei, H., Han, J., Fustero, S., Medio‐Simón, M., Sedgwick, D. M., Santi, C., Ruzziconi, R., & Soloshonok, V. A. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201901840 · Cited by 461 · see citing works

Phenols in Pharmaceuticals: Analysis of a Recurring Motif

Scott, K. A., Cox, P. B., & Njardarson, J. T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00223 · Cited by 217 · see citing works

Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity

Yu, Y., Liu, A., Dhawan, G., Mei, H., Zhang, W., Izawa, K., Soloshonok, V. A., & Han, J. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.05.042 · Cited by 182 · see citing works

Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review

Donnez, J., & Dolmans, M.-M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051085 · Cited by 182 · see citing works

Tailor‐Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals

Mei, H., Han, J., White, S., Graham, D. J., Izawa, K., Sato, T., Fustero, S., Meanwell, N. A., & Soloshonok, V. A. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000617 · Cited by 133 · see citing works

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study

Osuga, Y., Seki, Y., Tanimoto, M., Kusumoto, T., Kudou, K., & Terakawa, N. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.07.055 · Cited by 97 · see citing works

Dienogest and the Risk of Endometriosis Recurrence Following Surgery: A Systematic Review and Meta-analysis

Zakhari, A., Edwards, D., Ryu, M., Matelski, J. J., Bougie, O., & Murji, A. (2020) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2020.05.007 · Cited by 86 · see citing works

Synthetic Approaches to New Drugs Approved During 2016

Flick, A. C., Ding, H. X., Leverett, C. A., Fink, S. J., & O’Donnell, C. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00260 · Cited by 70 · see citing works

Breakthrough Bleeding in Transgender and Gender Diverse Adolescents and Young Adults on Long-Term Testosterone

Grimstad, F. W., Kremen, J., Shim, J. Y., Charlton, B. M., & Boskey, E. R. (2021) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2021.04.004 · Cited by 69 · see citing works

Synthetic Approaches to New Drugs Approved during 2018

Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Helal, C. J., DeForest, J. C., Morse, P., Mahapatra, S., & O’Donnell, C. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00345 · Cited by 66 · see citing works

Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas

Dababou, S., Garzon, S., Laganà, A. S., Ferrero, S., Evangelisti, G., Noventa, M., D’Alterio, M. N., Palomba, S., Uccella, S., Franchi, M. P., et al. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1957830 · Cited by 65 · see citing works

Structure of the human gonadotropin-releasing hormone receptor GnRH1R reveals an unusual ligand binding mode

Yan, W., Cheng, L., Wang, W., Wu, C., Yang, X., Du, X., Ma, L., Qi, S., Wei, Y., Lu, Z.-L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19109-w · Cited by 59 · see citing works

GnRH Antagonists with or without Add-Back Therapy: A New Alternative in the Management of Endometriosis?

Donnez, J., & Dolmans, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111342 · Cited by 49 · see citing works

Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality

Rekha, T. N., & Shin, D. (2023) · Pharmaceuticals · doi:10.3390/ph16030339 · Cited by 45 · see citing works

Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis

Yan, H., Shi, J., Li, X., Dai, Y., Wu, Y., Zhang, J., Gu, Z., Zhang, C., & Leng, J. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.08.856 · Cited by 40 · see citing works

Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis

Xin, L., Ma, Y., Ye, M., Chen, L., Liu, F., & Hou, Q. (2023) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06862-0 · Cited by 40 · see citing works

Novel pharmacological therapies for the treatment of endometriosis

Buggio, L., Dridi, D., Barbàra, G., Merli, C. E. M., Cetera, G. E., & Vercellini, P. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2117155 · Cited by 38 · see citing works

Gonadotropin-releasing hormone analogs: Mechanisms of action and clinical applications in female reproduction

Wu, H., Chang, H., & Leung, P. C. K. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100876 · Cited by 36 · see citing works

Gonadotropin-releasing hormone analog therapeutics

Newton, C. L., Riekert, C., & Millar, R. P. (2018) · Minerva Obstetrics and Gynecology · doi:10.23736/s0026-4784.18.04316-2 · Cited by 32 · see citing works

Physiological and pharmacological overview of the gonadotropin releasing hormone

Casati, L., Ciceri, S., Maggi, R., & Bottai, D. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115553 · Cited by 31 · see citing works

Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

Ali, M. K., Sara, A. R., & Hendy, A. A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1900726 · Cited by 30 · see citing works

GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives

Ciebiera, M., Madueke-Laveaux, O. S., Feduniw, S., Ulin, M., Spaczyński, R., Zgliczyńska, M., Bączkowska, M., Zarychta, E., Łoziński, T., Ali, M. K., et al. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2248890 · Cited by 29 · see citing works

Abnormal uterine bleeding: The well-known and the hidden face

Leal, C. R. V., Vannuccini, S., Jain, V., Dolmans, M., Sardo, A. D. S., Al-Hendy, A. A., & dos Reis, F. M. (2024) · Journal of Endometriosis and Uterine Disorders · doi:10.1016/j.jeud.2024.100071 · Cited by 27 · see citing works

Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?

Rzewuska, A., Żybowska, M., Sajkiewicz, I., Spiechowicz, I., Żak, K., Abramiuk, M., Kułak, K., & Tarkowski, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031008 · Cited by 27 · see citing works

Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome

Khan, M. S., Kim, H., Kim, R., Yoon, S. H., & Kim, S. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087454 · Cited by 25 · see citing works

Profile of Linzagolix in the Management of Endometriosis, Including Design, Development and Potential Place in Therapy: A Narrative Review

Donnez, J., Cacciottola, L., Squifflet, J.-L., & Dolmans, M. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s269976 · Cited by 22 · see citing works

Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data

Neri, M., Melis, G. B., Giancane, E., Vallerino, V., Pilloni, M., Piras, B., Loddo, A., Paoletti, A. M., & Mais, V. (2019) · International Journal of Women s Health · doi:10.2147/ijwh.s185023 · Cited by 19 · see citing works

The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications

Barretta, M., Vignali, M., Marca, A. L., & Grandi, G. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2441981 · Cited by 18 · see citing works

Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment

Ng, J., Duan, W. R., Marbury, T. C., Schmidt, J. M., & Klein, C. E. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.640 · Cited by 18 · see citing works

A review of phase II and III drugs for the treatment and management of endometriosis

Perrone, U., Evangelisti, G., Laganà, A. S., Bogliolo, S., Ceccaroni, M., Izzotti, A., Gustavino, C., Ferrero, S., & Barra, F. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2296080 · Cited by 17 · see citing works

Update on the management of endometriosis-associated pain in France

Fernandez, H., Agostini, A., Baffet, H., Chabbert‐Buffet, N., Descamps, P., Estrade, J.-P., Giraudet, G., Hocké, C., Salle, B., Trémollières, F., et al. (2023) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2023.102664 · Cited by 16 · see citing works

Review of human genetic and clinical studies directly relevant to GnRH signalling

Seminara, S. B., & Topaloglu, A. K. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13080 · Cited by 15 · see citing works

Design and synthesis of fluorine aromatic scaffolds containing drugs approved by the US FDA from 2002 to 2022

Xu, P., Zhu, L., Zhang, D., Li, Z., Ge, R., & Tian, Q. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101446 · Cited by 13 · see citing works

The potential role of elagolix for treating uterine bleeding associated to uterine myomas

Barra, F., Vitale, S. G., Seca, M., Scala, C., Maggiore, U. L. R., Cianci, A., & Ferrero, S. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1755254 · Cited by 13 · see citing works

Relugolix for the treatment of uterine fibroids

Rocca, M. L., Palumbo, A., Lico, D., Fiorenza, A., Bitonti, G., D‘Agostino, S., Gallo, C., Carlo, C. D., Zullo, F., & Venturella, R. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787988 · Cited by 11 · see citing works

Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids

Evangelisti, G., Barra, F., Perrone, U., Donato, N. D., Bogliolo, S., Ceccaroni, M., & Ferrero, S. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2113381 · Cited by 11 · see citing works

Efficacy of Dienogest Versus GnRH Agonists After Endometriosis Surgery: A Systematic Review and Meta-Analysis

Servidoni, A. C. P., Martin, G. D. C., Gaio, G. D. S., Amador, W. F. O., dos Santos, P. L., Andres, M. P., Abrão, D. C., & Taylor, H. S. (2025) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2025.11.008 · Cited by 9 · see citing works

The role of elagolix in the suppression of ovulation in donor oocyte cycles

Boniface, C., Schnorr, J., Gray, J., McLaughlin, J. E., Cook, H., Slowey, M., & Schnorr, J. (2023) · F&S Reports · doi:10.1016/j.xfre.2023.03.006 · Cited by 9 · see citing works

Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States

Poulos, C. M., Soliman, A. M., Tekin, S., & Agarwal, S. K. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1832468 · Cited by 9 · see citing works

Fertility Preservation in Women With Malignancy: Future Endeavors

Blumenfeld, Z. (2019) · Clinical Medicine Insights Reproductive Health · doi:10.1177/1179558119872490 · Cited by 9 · see citing works

Elagolix as a Novel Treatment for Endometriosis-Related Pain

Fantasia, H. C. (2019) · Nursing for Women s Health · doi:10.1016/j.nwh.2019.05.004 · Cited by 7 · see citing works

Analytical methodology and pharmacokinetic study of elagolix in plasma of rats using a newly developed UPLC-MS/MS assay

Wang, Q., Gu, E.-M., Chen, C., Xu, R.-A., & Luo, S. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103235 · Cited by 7 · see citing works

The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study

Soliman, D., Naoom, R., Zaied, M., & Soliman, S. (2024) · F&S Reports · doi:10.1016/j.xfre.2024.06.006 · Cited by 6 · see citing works

Assessment of Quality of Life among Elderly Patients Attending Primary Healthcare Centers in Aseer Region, Saudi Arabia

Alqahtani, O. M., AlSamghan, A. S., Alsaleem, S. A., Alyahya, A. A. S., Alrazhi, F. S., Alshahrani, A. S., Alasmari, A. S. M., Saeed, A. A., Qawwadi, R. A. N., Alotayfi, B. M., et al. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251375 · Cited by 6 · see citing works

Elagolix Sodium Salt and Its Synthetic Intermediates: A Spectroscopic, Crystallographic, and Conformational Study

Ciceri, S., Colombo, D., Fassi, E. M. A., Ferraboschi, P., Grazioso, G., Grisenti, P., Iannone, M., Castellano, C., & Meneghetti, F. (2023) · Molecules · doi:10.3390/molecules28093861 · Cited by 5 · see citing works

Elagolix Represents a Less Invasive and Cheaper Option Than Injectable GnRH Antagonist for Ovulation Suppression in IVF

Mouanness, M., & Merhi, Z. O. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae168 · Cited by 5 · see citing works

Diethylzinc Amylates: Selective Iodine–Zinc Exchange Reagents at Room Temperature

Trauner, F., Boutet, B., Rambaud, F., Ngo, V. N., & Didier, D. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c01924 · Cited by 5 · see citing works

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis

Stodtmann, S., Nader, A. M., Polepally, A. R., Suleiman, A. A., Winzenborg, I., Noertersheuser, P. A., Ng, J., Mostafa, N. M., & Shebley, M. (2021) · Clinical and Translational Science · doi:10.1111/cts.13040 · Cited by 5 · see citing works

Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle

Gingold, J. A., Jain, M., & Jalai, C. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-99596-6_1 · Cited by 5 · see citing works

Experimental and new investigational drugs for the treatment of uterine fibroids

Evangelisti, G., Ferrero, S., Perrone, U., Gustavino, C., Volpi, E., Izzotti, A., & Barra, F. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2343786 · Cited by 4 · see citing works

Pharmacokinetic considerations for gonadotropin-releasing hormone agonists and antagonists to treat endometriosis

Paoletti, A. M., Neri, M., Pilloni, M., Marotto, M. F., Giancane, E., Vallerino, V., Piras, B., Melis, G., Melis, V., Masciale, M. D. M., et al. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2499550 · Cited by 4 · see citing works

STRUCTURE CHARACTERIZATION OF STRESS DEGRADATION PRODUCTS OF ELAGOLIX BY USING HRMS, NMR

Kotha, S. S. K. C., Pulletikurthi, K. V. K. M., Doddipalla, R., Kavitapu, D., Rumalla, C. S., Gandham, H., & Kaliyaperumal, M. (2022) · RASAYAN Journal of Chemistry · doi:10.31788/rjc.2022.1516527 · Cited by 4 · see citing works

An Evidence-Based Review of Elagolix for the Treatment of Pain Secondary to Endometriosis

Urits, I., Adamian, L., Miro, P., Callan, J., Patel, P. M., Patel, M., Berger, A. A., Kassem, H., Kaye, A. D., & Viswanath, O. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4390 · Cited by 4 · see citing works

Knowledge, attitudes, and practices of self-ear cleaning among the general population in Riyadh, Saudi Arabia

Abdulrahman, K. A. B., Alhazani, F. A., Alayed, F. T., Alomar, A. A., AlSarrani, A. H., Albalawi, A. M., & Alhussini, F. O. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251370 · Cited by 4 · see citing works

Acute intermittent porphyria: a disease with low penetrance and high heterogeneity

Lei, J.-J., Li, S., Dong, B.-X., Yang, J., & Ren, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1374965 · Cited by 4 · see citing works

Clinical Pharmacology at the Intersection of Women's Health and Regulation: Drug Development Considerations for Uterine Fibroids

Shon, J., Zou, P., Tran, D. C., Seo, S. K., & Lu, Y. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1736 · Cited by 4 · see citing works

Recent Advances in the Synthesis of 5-(Hetero)aryl Uracil Derivatives

Cheng, L., Wang, Z., Liu, A., & Liu, L. (2023) · Synlett · doi:10.1055/a-2091-1071 · Cited by 4 · see citing works

Direct Stereoselective Method Development and Validation of Elagolix on Zwitterionic Chiral Stationary Phase by High-Pressure Liquid Chromatography

Choppari, T., Srinivasu, G., Chennuru, L. N., & Cherla, P. M. (2020) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2020.120513 · Cited by 4 · see citing works

Medical Management of Endometriosis in Adolescent and Young Adult Women: A Review of 91 Cases of Biopsy-Confirmed Endometriosis

Li, H. J., Esencan, E., Song, Y., Taylor, H. S., Cho, Y., & Vash‐Margita, A. (2024) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2024.102562 · Cited by 3 · see citing works

Novel non-peptide uracil-derived human gonadotropin-releasing hormone receptor antagonists

Ciceri, S., Fassi, E. M. A., Vezzoli, V., Bonomi, M., Colombo, D., Ferraboschi, P., Grazioso, G., Grisenti, P., Villa, S., Castellano, C., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116903 · Cited by 3 · see citing works

Elagolix in endometriosis-related pain: a profile of its use as approved in the USA

Lyseng-Williamson, K. A. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00606-y · Cited by 3 · see citing works

Thromboembolic safety profile of low-dose estradiol (valerate) in combined hormonal preparations: Implications for the development of new hormonal endometriosis and uterine fibroid therapies

Barnett, C., Bauerfeind, A., von Stockum, S., & Heinemann, K. (2021) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.1177/22840265211019546 · Cited by 3 · see citing works

Elagolix Sodium: Novel GnRH Antagonist for the Treatment of Endometriosis

Bhatia, R. (2021) · doi:10.52916/jcar214007 · Cited by 3 · see citing works

Predictive factors of postoperative paralytic ileus following abdominal surgery: a clinical study

Abdelrahman, T. M., Alharthi, A. K., Alamri, S., Alnefaie, A. M., Omar, B., & Alzahrani, M. A. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251361 · Cited by 3 · see citing works

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women

Nader, A. M., Mostafa, N. M., Kim, E., & Shebley, M. (2022) · Clinical and Translational Science · doi:10.1111/cts.13247 · Cited by 2 · see citing works

Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population

Zhang, X., Wang, X., Li, R., Zhang, C., Du, J., Zhao, H., & Wen, Q. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01402-2 · Cited by 2 · see citing works

LC–MS-Compatible Chromatographic Method for Quantification of Potential Organic Impurities of Elagolix Sodium in Tablet Dosage Form with Identification of Major Degradation Products

Desai, P. R., Prajapati, R., & Chokshi, A. B. (2023) · Journal of AOAC International · doi:10.1093/jaoacint/qsad019 · Cited by 2 · see citing works

Medikamentöse Therapie der Endometriose

Burghaus, S., & Beckmann, M. W. (2024) · Die Gynäkologie · doi:10.1007/s00129-024-05198-x · Cited by 1 · see citing works

The effect of dienogest treatment on anti-Mullerian hormone in patients with endometrioma: a 12-month follow-up study

Karataş, E., Temiz, B. E., Mümüşoğlu, S., Yaralı́, H., & Bozdağ, G. (2024) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.galenos.2024.2022-9-4 · Cited by 1 · see citing works

Awareness and attitude toward antidepressants in the population of Riyadh, Saudi Arabia

Alsenaidi, Y. I., AlDawas, O., AlFihaid, A., AlZimami, M., AlQahtani, R., & Abdulrahman, K. A. B. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251360 · Cited by 1 · see citing works

SHR7280, an oral gonadotropin-releasing hormone antagonist, for the prevention of premature luteinizing hormone surge in controlled ovarian hyperstimulation: a dose-finding, phase 2 trial

Chi, H., Song, Y., Jin, L., Song, X., Wang, X., Ma, Q., Cao, Y., Liang, X., Tan, J., Guan, Y., et al. (2025) · Human Reproduction · doi:10.1093/humrep/deaf082 · Cited by 1 · see citing works

Functionalization of λ5-Phosphinines via metalation strategies

Rambaud, F., Fotie, B. T., Naumann, R., Heinze, K., & Didier, D. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01822-6 · Cited by 1 · see citing works

Neue Behandlungsmöglichkeiten der Endometriose mit GnRH-Antagonisten

Küpker, W., & Felberbaum, R. E. (2020) · Der Gynäkologe · doi:10.1007/s00129-020-04633-z · Cited by 1 · see citing works

Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias

Ma, C. D., & Bonkovsky, H. L. (2022) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2022.100915 · Cited by 1 · see citing works

Exogenous Hormone-Induced Endometrial Changes

Wong, Y. P., Tan, G. C., & Khong, T. Y. (2025) · Springer eBooks · doi:10.1007/978-981-97-4822-8_56 · Cited by 1 · see citing works

Assessment of level of knowledge about cryptorchidism and its complications among paternity age population in the western region of Saudi-Arabia. Cross-sectional Questionnaire based study

Alfadli, F. M., Aljuaid, A., Althbaiti, M. A., Alhamyani, A. D., Alsoaimi, A. S., & Alzahrani, K. M. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251368 · Cited by 1 · see citing works

Vascular dementia - A Narrative Review

Alzbeidi, N., Alsinawi, H., & Phaterphaker, H. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251395 · Cited by 1 · see citing works

Knowledge, Attitude and Perceptions of the population towards Vitamin D in Jeddah, Saudi Arabia

El-Gamal, F., Daghmash, A., Yapah, A., Buraymah, A., Tahawi, F. A., & Khairurllah, F. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251364 · Cited by 1 · see citing works

The Prevalence of Constipation and Its Associated Complications in Aseer Region by Using Wexner Scale

Bhat, M. J., Alkorbi, S. M. A., Almaem, N. M. M., Alqarni, A. O. M., Alamri, S. A. A., Asiri, L. G., & Alsaiary, K. A. A. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251365 · Cited by 1 · see citing works

Neue Behandlungsoptionen mit GnRH-Antagonisten bei Endometriose und Uterus myomatosus

Küpker, W., Plathow, D., Bullerdiek, J., & Felberbaum, R. E. (2020) · Gynäkologische Endokrinologie · doi:10.1007/s10304-020-00329-8

Gonadotrophin-releasing hormone receptors in GtoPdb v.2021.3

Heitman, L. H., IJzerman, A. P., McArdle, C. A., & Pawson, A. J. (2021) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f31/2021.3

Suplemento do IX Congresso SAMMG

(2021) · Revista Médica de Minas Gerais · doi:10.5935/2238-3182.v31supl.2

Efficacy of Dienogest for Prevention of Endometriosis Recurrence: A Systematic Review and Meta-Analysis

Assiri, H. M., Alomari, M. A., Alshehri, A., Alahmari, A. S., & Alasmari, M. M. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251391

Association Between Blood Donation and Improved Sleep Quality Among Blood Donors in Aseer Region

Alshibli, M. A., Asiri, Z. M. A., Ghanem, G. A. M. A., Shibli, M. A. A., Alotaibi, N. M., Alasmari, S. A. S., safar, A. S. S. A., Alshahrani, B. S. S., Albarqi, N. H., Alqahtani, N. S. S., et al. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251366

Parental awareness of pediatric foreign body aspiration in Taif city, Saudi Arabia

Alam, B. S., Althomali, M. A., Jawhari, A. M., Faraj, K., Alghuraibi, A., Alsubaie, A., & Aljuaid, S. M. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251367

Assessment of patients’ knowledge and attitudes towards self-insulin administration and skin manifestations in the regions of Aseer

Shawabkeh, R., Aldajam, M., Alshehri, H., Muqri, M., Mukharrib, M., Alzamanan, M., Alhamad, M., Alhamad, S., Alnumayr, H., Aldajam, M., et al. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251387

Medical students’ understanding and interpreting abilities for Complete Blood Counts (CBC) in clinical practice

Jameel, T., Baig, M., Albejad, M. I. M., Aljifri, T. M. A., Almaghrabi, B. A. T., & Qashqaui, R. Y. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251363

Elastography as predictor for thyroid nodule malignancy

Alsuqair, R., Omar, N., Alshreef, S., Alharthi, Y., Algarni, M., Aljuaid, A., & AlThaqufi, O. J. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251378

Burden, clinical aspects and correlates of dyspepsia among the population in Jeddah, Saudi Arabia

El-Gamal, F., Baajajah, L., Katib, G., & aljohani, S. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95251362

Actualización sobre las posibilidades de tratamiento médico hormonal para el sangrado menstrual abundante

Estadella, J., Perelló-Capó, J., & Sánchez, R. M. (2022) · Clínica e Investigación en Ginecología y Obstetricia · doi:10.1016/j.gine.2022.100819

Gonadotrophin-releasing hormone receptors in GtoPdb v.2023.1

Heitman, L. H., IJzerman, A. P., McArdle, C. A., & Pawson, A. J. (2023) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f31/2023.1

UHPLC-MS/MS Method Development and Validation for the Genotoxic Impurities Trimethyl Phosphate and Triisopropyl Phosphate of Elagolix Sodium

Hao, Y., Feng, Z., Zhuang, X., Teng, H., & Zhang, G. (2023) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmad038

Exogenous Hormone-Induced Endometrial Changes

Wong, Y. P., Tan, G. C., & Khong, T. Y. (2024) · Springer eBooks · doi:10.1007/978-981-19-7696-4_56-1

Orale GnRH-Antagonisten in der kontrollierten ovariellen Stimulation: noch viele Fragen offen

Felberbaum, R. E., Küpker, W., & Diedrich, K. (2024) · Die Gynäkologie · doi:10.1007/s00129-024-05280-4

Elagolix - a novel drug for management of endometriosis and uterine fibroids

Khan, F. (2025) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20252375

Pharmacokinetic–Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist

Bae, S. H., Kang, J., Jeon, S., Kim, S. M., Kim, H.-T., Han, S., & Han, S. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01595-0

Atypical gelation of Elagolix sodium in aqueous media: Mechanistic insights and Inhibition via coamorphization

Shi, J., Shen, P., Zhang, X., 苏美玲, Tang, M., Gao, Y., Zhang, J., Qian, S., & Wei, Y. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115022

Morphological modulation of ovarian endometrioma with elagolix: a case report

Maladkar, M. N., Patani, N., Tekchandani, C. M., & Patil, R. (2026) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20261297

Elagolix in endometriosis-related pain: a profile of its use as approved in the USA

Lyseng-Williamson, K. A. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00606-y · Cited by 3 · see citing works

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix

Chwalisż, K. (2023) · F&S Reports · doi:10.1016/j.xfre.2023.02.002 · Cited by 6 · see citing works

Elagolix for endometriosis: all that glitters is not gold

Vercellini, P., Viganò, P., Barbàra, G., Buggio, L., Somigliana, E., ‘Luigi Mangiagalli’ Endometriosis Study Group, Aimi, G., Alberico, D., Barbàra, G., Benaglia, L., et al. (2018) · Human Reproduction · doi:10.1093/humrep/dey368 · Cited by 45 · see citing works

A Clinician's Guide to the Treatment of Endometriosis with Elagolix

Leyland, N. A., Estes, S. J., Lessey, B. A., Advincula, A. P., & Taylor, H. S. (2020) · Journal of Women s Health · doi:10.1089/jwh.2019.8096 · Cited by 41 · see citing works

Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain

Barra, F., Scala, C., & Ferrero, S. (2019) · Drugs of today · doi:10.1358/dot.2019.55.4.2930713 · Cited by 26 · see citing works